Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
http://img.marketwire.com/rss/mwPBBI.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced  clinical  company  february  marketwired february  marketwired  neptune  offering  pieris  public offering  shares 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech



Marketwired - Biotech



Last Build Date: Fri, 16 Feb 2018 18:07:33 EST

Copyright: Copyright: (C) Marketwired
 



Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

Fri, 16 Feb 2018 17:36:17 EST

BOSTON, MA--(Marketwired - February 16, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are $50.6 million. 6,325,000 shares of common stock at a public offering price of $8.00 per share were issued and sold in the offering, which includes 825,000 shares issued upon the exercise of the underwriters' option to purchase additional shares, less the underwriting discounts and commissions.




Moleculin Announces Pricing of $9 Million Registered Direct Offering

Fri, 16 Feb 2018 08:28:56 EST

HOUSTON, TX--(Marketwired - February 16, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $9 million. The closing of the offering is expected to take place on or about February 21, 2018, subject to the satisfaction of customary closing conditions.




Vivakor Announces Oil Reclamation Contract in Kuwait

Thu, 15 Feb 2018 11:49:13 EST

LAS VEGAS, NV--(Marketwired - February 15, 2018) - Vivakor Inc. (OTC PINK: VIVK) announced today that Vivakor Middle East, based in Doha, Qatar has been engaged by The Energy Resource Institute (TERI) to complete a remediation contract for Kuwait Oil Company (KOC).




Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment

Thu, 15 Feb 2018 08:30:00 EST

Cutting Edge Science Suggests New Molecule Is Capable of Shutting Down Tumor Activity




Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model

Thu, 15 Feb 2018 07:00:00 EST

NORWOOD, MA--(Marketwired - February 15, 2018) -

  • Study identifies lenabasum as important upstream trigger of resolution of innate immune responses
  • Data provides mechanistic validation of positive clinical data reported from Company's Phase 2 clinical studies in systemic sclerosis, cystic fibrosis and dermatomyositis



Neptune annonce ses résultats pour le troisième trimestre

Wed, 14 Feb 2018 16:30:22 EST

Les activités du secteur du cannabis progressent comme prévu




Neptune Announces Third Quarter Results

Wed, 14 Feb 2018 16:00:00 EST

Cannabis Business Development Underway and On Schedule




Novoheart Signs Agreement with Sumocor to Develop Novel Therapeutics for Heart Failure

Wed, 14 Feb 2018 09:11:03 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 14, 2018) - Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH), through its wholly owned US subsidiary, has entered into a commercial agreement with Sumocor LLC ("Sumocor"), a biotech company based in New York City that is focused on the development of therapeutics for cardiovascular diseases. Pursuant to the agreement, Novoheart will test Sumocor's candidate therapeutics in three phases on Novoheart's MyHeartT Platform of human bioengineered heart constructs, to provide thorough pre-clinical assessment of efficacy and cardiotoxicity in the context of the human heart tissues and chambers in preparation for filing an Investigational New Drug (IND) application to the United States Food and Drug Administration by Sumocor.




Avalon GloboCare Subsidiary GenExosome Expands Operations into the United States

Wed, 14 Feb 2018 08:00:00 EST

Launches US headquarters for marketing and distribution of proprietary Exosome Isolation System

Announces plans to introduce proprietary diagnostic and therapeutic products leveraging exosome technology




Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference

Wed, 14 Feb 2018 07:00:00 EST

Live fireside chat presentation and webcast on Thursday, February 22 at 3:35 p.m. EST




Oncolytics Biotech(R) to Present at the RBC Capital Markets 2018 Healthcare Conference

Wed, 14 Feb 2018 07:00:00 EST

CALGARY, AB and SAN DIEGO, CA--(Marketwired - February 14, 2018) - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors "hot", today announced that it will present at the RBC Capital Markets 2018 Healthcare Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 3:05 pm ET, on Wednesday, February 21, 2018 in the Kennedy II Room on the fourth floor of The Lotte New York Palace Hotel. The conference takes place on February 21st & 22nd in New York, NY.




Pieris Pharmaceuticals Announces Pricing of its Public Offering

Wed, 14 Feb 2018 00:27:18 EST

BOSTON, MA--(Marketwired - February 14, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the pricing of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are expected to be $44.0 million. In addition, Pieris has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about February 16, 2018, subject to customary closing conditions.




Pieris Pharmaceuticals Announces Public Offering of Common Stock

Tue, 13 Feb 2018 16:01:00 EST

BOSTON, MA--(Marketwired - February 13, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Pieris intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering will be sold by Pieris.




Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer

Tue, 13 Feb 2018 08:30:00 EST

HOUSTON, TX--(Marketwired - February 13, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has entered into an agreement with Emory University to enable expanded cancer research on Moleculin's WP1066 molecule for the possible treatment of medulloblastoma, a pediatric malignant primary brain tumor.




VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results

Mon, 12 Feb 2018 16:30:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - February 12, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported financial results for its third fiscal quarter ended December 31, 2017.




Neptune et Tetra Bio-Pharma concluent une entente de codéveloppement de produits antidouleurs et anti-inflammatoires à base d'huiles de cannabinoïdes purifiés

Mon, 12 Feb 2018 12:43:09 EST

LAVAL, QUÉBEC--(Marketwired - 12 fév. 2018) - Neptune Technologies & Bioressources inc. (« Neptune ») (NASDAQ:NEPT)(TSX:NEPT) et Tetra Bio-Pharma Inc. (« Tetra ») (TSX CROISSANCE:TBP)(OTCQB:TBPMF) ont annoncé aujourd'hui la conclusion d'une entente de codéveloppement, de commercialisation et de mise en marché de produits à base d'huiles de cannabinoïdes purifiés contre la douleur et l'inflammation à l'intention des marchés des produits de santé naturelle et de la médecine vétérinaire.




Cerecor to Acquire Avadel Pharmaceuticals' Pediatric Assets

Mon, 12 Feb 2018 09:07:00 EST

Transaction is immediately accretive to revenue and earnings

Expands Cerecor's pipeline via an exclusive license to use Avadel's LiquiTime(R) and Micropump(R) technology in four pediatric drug candidates




Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

Mon, 12 Feb 2018 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Feb. 12, 2018) - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) and Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.




Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

Mon, 12 Feb 2018 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Feb. 12, 2018) - Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.